Triple board certified: Cardiovascular disease & internal medicine.

Pedro Martinez-Clark is a world-renowned physician in Miami, Florida. Having earned his medical degree at Colombia’s acclaimed Universidad del Norte in the city of Barranquilla, Pedro traveled to Ohio’s Case Western Reserve University to begin his post-graduate medical training in Internal Medicine. Having excelled and made a name for himself in the northeast, Dr. Martinez-Clark placed into one of the United States’ most competitive Clinical Fellowships in Cardiovascular Disease (Cardiology), at Beth Israel Deaconess Medical Center, Harvard Medical School. At Harvard, he obtained further fellowship training in Interventional Cardiology, Endovascular Therapies and Vascular Medicine. During his stay at Harvard, Dr. Martinez-Clark participated in many clinical trials, research projects and started his involvement in medical device innovation. It would be no surprise that 8 years later, Dr. Martinez-Clark would become recognized, globally for excellence in medical care, research efforts and medical innovation contributions. In addition to caring for patients, Dr. Martinez-Clark works very closely with several public and private organizations with the common goal of improving the healthcare innovation ecosystem in South Florida.

From the medical innovation perspective, Dr. Martinez-Clark has been involved in several medical device development efforts. Some of these technologies include:

Pedro Martinez-Clark 1-16 CV from Pedro Martinez-Clark

Microprocessor controlled percutaneous aortic valve replacement which allows unparalleled precision and low tissue-device contact force at the time of implantation. This project has completed chronic animal experiments and is currently undergoing a second round of funding in order to start human trials.
Percutaneous annuloplasty for the treatment of functional mitral regurgitation in patients with heart failure. The global clinical trial has been completed and the data has been submitted to the European Committee for device registration.
Trans-Apical annuloplasty for the treatment of functional mitral regurgitation using a hybrid combined approach of surgical and percutaneous techniques. Feasibility study in humans has been completed.
One of the original researchers that described the transcaval access to the cardiovascular system, a novel percutaneous approach that allows patients with peripheral vascular disease undergo percutaneous procedures with minimal risk. Dr. Martinez-Clark co-founded TransCaval Solutions, Inc., a medical device company dedicated to create purpose built access and closure technology that facilitates the transcaval access. The technique won the Best of the Best Abstract Award at The Society for Cardiovascular Angiography and Interventions (SCAI)'s 2014 meeting. Dr. Martinez-Clark obtained funding from private investors to develop and market his medical device to treat over 154,000 patients annually who can not be treated with conventional technical devices, thus creating a $ 2.2 billion market opportunity in 2020.
Corquest Inc., percutaneous access to the right atrium with application in structural heart disease. This technology was tested in animals and cadavers and was sold to Cardio3, a medical device company from Belgium in the regenerative medicine space.

To learn more about Dr. Martinez-Clark’s research and technology innovation efforts refer to his CV or contact us directly.